<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051163</url>
  </required_header>
  <id_info>
    <org_study_id>REC.REF.2020-165</org_study_id>
    <secondary_id>HS1277ES</secondary_id>
    <nct_id>NCT05051163</nct_id>
  </id_info>
  <brief_title>Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition</brief_title>
  <acronym>REDMOTHIV</acronym>
  <official_title>A Randomized Trial to Investigate Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition in Mulago Hospital, Kampala, Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study to investigate whether empiric use of an antibiotic with greater antimicrobial&#xD;
      sensitivity (ceftriaxone) than standard-of-care (ampicillin plus gentamicin) will reduce&#xD;
      mortality among HIV-infected/HEU children admitted to Mwanamugimu Nutrition Unit, Mulago&#xD;
      Hospital, Kampala, Uganda.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      HIV-infected and HIV-exposed-uninfected children (HEU) are at increased risk of developing&#xD;
      malnutrition. Severely malnourished children have high mortality rates, but mortality is&#xD;
      higher in those that are HIV-infected. Preliminary audits at the Mwanamugimu Nutrition Unit,&#xD;
      Mulago Hospital, in 2014 showed that 43% of the severely malnourished children that died were&#xD;
      HIV-infected/HEU, despite only 30% of admissions being HIV-infected/HEU, with deaths due to&#xD;
      infections in 90% of cases.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
      This study aims to investigate whether empiric use of an antibiotic with greater&#xD;
      antimicrobial sensitivity (ceftriaxone) than standard-of-care (ampicillin plus gentamicin)&#xD;
      will reduce mortality among HIV-infected/HEU children admitted to Mwanamugimu Nutrition Unit.&#xD;
      Secondary objectives include: comparing length of hospitalization, weight-for-height,&#xD;
      weight-for-age and height-for-age z-scores between ceftriaxone versus standard of care&#xD;
      (ampicillin and gentamicin) treatment arms; ascertaining the pattern/antimicrobial&#xD;
      sensitivity of pathogens among participants; determining the prevalence and factors&#xD;
      associated with HIV-infection among severely malnourished children; and evaluating the&#xD;
      pharmacokinetics (PK) of lopinavir/ritonavir (LPV/r) among severely malnourished HIV-infected&#xD;
      children.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      This will be an open label randomized controlled trial involving 300 children; 76&#xD;
      HIV-infected (current mortality - 33%) and 224 HEU (current mortality - 26%). The&#xD;
      participants will be randomized to receive 1week of ceftriaxone (n= 150) or standard-of-care&#xD;
      (ampicillin/gentamicin) (n=150), in addition to other routine care; the ratio of HIV-infected&#xD;
      to HEU (1:3) in this sample is reflective of the current proportions of the HIV-infected and&#xD;
      HEU children admitted at Mwanamugimu Nutrition Unit. The trial's primary outcome will be in&#xD;
      hospital mortality. 300 randomised children provides &gt;80% power to detect reductions in&#xD;
      mortality from the expected 28% to 14%, allowing for 10% noncompliance/lost-to-follow-up in&#xD;
      each group. Secondary outcomes will be: length of hospitalization; weight-for-height,&#xD;
      weight-for-age and height-for-age z-scores; and pattern/antimicrobial sensitivity of&#xD;
      pathogens. In addition, 280 severely malnourished children of unknown serostatus will be&#xD;
      tested for HIV at admission to determine the prevalence and factors associated with&#xD;
      HIV-infection. 280 children provide 80% power to determine the prevalence of HIV-infection.&#xD;
      Furthermore, all the HIV-infected children on LPV/r will each provide sparse pharmacokinetic&#xD;
      (PK) samples to evaluate the PK of LPV/r among malnourished children. In this PK sub-study,&#xD;
      geometric means of steady-state LPV PK parameters [Area Under the Curve (AUC) 0-12h, maximum&#xD;
      concentration (Cmax) and concentration at 12 hours after dose (C12h)] will be determined. The&#xD;
      PK parameters (AUC 0-12h, Cmax, C12) will then be put in pharmacokinetic-pharmacodynamic&#xD;
      (PK-PD) models to determine optimal doses for the study population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">June 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label parallel group randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In hospital mortality</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cumulative incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>90 days</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-for-height z-score</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-for-age z-score</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height-for-age z-score</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern and antimicrobial sensitivity of pathogens</measure>
    <time_frame>7 days</time_frame>
    <description>Frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV infection</measure>
    <time_frame>Baseline</time_frame>
    <description>Prevalence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC 0- 12h)</measure>
    <time_frame>12hours</time_frame>
    <description>Geometric means</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>12hours</time_frame>
    <description>Geometric means</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12hours post dose (C12h)</measure>
    <time_frame>12hours</time_frame>
    <description>Geometric means</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Malnutrition, Child</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ampicillin and Gentamicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly&#xD;
Gentamicin will be administered intravenously at a dose 5mg/kg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone Sodium</intervention_name>
    <description>7 days of once daily dosing</description>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <other_name>ZEFONE-1000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin</intervention_name>
    <description>7 days of 6 hourly dosing</description>
    <arm_group_label>Ampicillin and Gentamicin</arm_group_label>
    <other_name>AMPIMAX-500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin</intervention_name>
    <description>7 days of once daily dosing</description>
    <arm_group_label>Ampicillin and Gentamicin</arm_group_label>
    <other_name>GENTAMICIN INJECTION</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-infected children aged 1 to 59 months admitted at Mwanamugimu Nutrition Unit with&#xD;
             severe acute malnutrition&#xD;
&#xD;
          2. HIV exposed but uninfected children aged 1 to 59 months admitted at Mwanamugimu&#xD;
             Nutrition Unit with severe acute malnutrition&#xD;
&#xD;
          3. For prevalence of HIV-infection sub-study, children presenting with severe acute&#xD;
             malnutrition on admission at Mwanamugimu Nutrition Unit.&#xD;
&#xD;
          4. For PK sub-study, the child should have been on antiretroviral therapy for at least&#xD;
             2weeks and should have been in hospital for at least 2weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For PK sub-study; a child with documented poor adherence to antiretroviral therapy.&#xD;
&#xD;
          -  For PK sub-study; a child known to have vomited the drug on the sampling day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Victor Musiime, PhD</last_name>
    <phone>+256772401749</phone>
    <email>musiimev@yahoo.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Makerere University College of Health Sciences</name>
      <address>
        <city>Kampala</city>
        <state>Central</state>
        <zip>7072</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Musiime, PhD</last_name>
      <phone>0772401749</phone>
      <email>musiimev@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Victor Musiime, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippa Musoke, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jackson Mukonzo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Willy Ssengooba, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Babirekere, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>College of Health Sciences</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Severe Acute Malnutrition</mesh_term>
    <mesh_term>Child Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>When results are required as part of a meta-analysis or as secondary data.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>1 year after end of data collection</ipd_time_frame>
    <ipd_access_criteria>On request to Principal Investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

